TEVA.TA : Summary for TEVA PHARMA IND ILS0.1 - Yahoo Finance

U.S. Markets closed

Teva Pharmaceutical Industries Limited (TEVA.TA)


Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Add to watchlist
11,370.00+90.00 (+0.80%)
As of 11:08AM IDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close11,280.00
Open11,400.00
Bid11,370.00 x 200
Ask11,390.00 x 34100
Day's Range11,370.00 - 11,410.00
52 Week Range111.80 - 11,410.00
Volume47,717
Avg. Volume600,284
Market Cap115.4B
BetaN/A
PE Ratio (TTM)162,428.58
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • 3 Dividend Stocks That Retirees Should Avoid
    Motley Fool16 hours ago

    3 Dividend Stocks That Retirees Should Avoid

    High dividend yields for CenturyLink, GlaxoSmithKline, and Teva look great, but there's more to the story for these stocks.

  • Reuters2 days ago

    Teva's new asthma inhaler poses first competition for GSK's Advair

    Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S. approval in January to make an inhaler similar to Advair, also launched a generic version of its own inhaler, AirDuo RespiClick. AirDuo is not a true generic of Advair, but contains the same two active ingredients, fluticasone propionate and salmeterol.

  • Business Wire3 days ago

    Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol

    Teva Pharmaceutical Industries Ltd., today announced the simultaneous launch of AirDuo™ RespiClick® inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist combination.